688062 迈威生物
已收盘 12-26 15:00:01
资讯
新帖
简况
每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床
证券之星 · 12-28 02:29
每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床
迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%
证券之星 · 12-25
迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
迈威生物（688062）披露股份回购实施结果公告，12月24日股价上涨0.99%
证券之星 · 12-24
迈威生物（688062）披露股份回购实施结果公告，12月24日股价上涨0.99%
迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可
智通财经 · 12-23
迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可
12月15日迈威生物跌6.05%，新华优选分红混合A基金重仓该股
证券之星 · 12-15
12月15日迈威生物跌6.05%，新华优选分红混合A基金重仓该股
迈威生物宣布创新抗St2抗体9Mw1911的IIa期试验结果显示年严重 COPD 加重率降低超过 40%
美股速递 · 12-01
迈威生物宣布创新抗St2抗体9Mw1911的IIa期试验结果显示年严重 COPD 加重率降低超过 40%
迈威生物（688062）自愿披露关于9MW1911临床研究进展的公告，12月1日股价下跌0.44%
证券之星 · 12-01
迈威生物（688062）自愿披露关于9MW1911临床研究进展的公告，12月1日股价下跌0.44%
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
每日经济新闻 · 12-01
百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参
迈威生物：9MW1911临床研究进展顺利COPD急性加重年化发生率显著降低
证券之星 · 11-30
迈威生物：9MW1911临床研究进展顺利COPD急性加重年化发生率显著降低
迈威生物（688062）披露关于开立、变更部分募集资金专用账户并重新签订三方及四方监管协议的公告，11月26日股价上涨2.47%
证券之星 · 11-26
迈威生物（688062）披露关于开立、变更部分募集资金专用账户并重新签订三方及四方监管协议的公告，11月26日股价上涨2.47%
新股消息 | 迈威生物(688062.SH)港股IPO获中国证监会备案
智通财经网 · 11-24
新股消息 | 迈威生物(688062.SH)港股IPO获中国证监会备案
每周股票复盘：迈威生物（688062）获H股发行备案
证券之星 · 11-23
每周股票复盘：迈威生物（688062）获H股发行备案
【财闻联播】美团将在全国建设“骑手公寓”！兆威机电、迈威生物港股IPO获证监会备案
券商中国 · 11-22
【财闻联播】美团将在全国建设“骑手公寓”！兆威机电、迈威生物港股IPO获证监会备案
迈威生物（688062）披露发行境外上市外资股（H股）获得中国证监会备案，11月20日股价上涨0.02%
证券之星 · 11-20
迈威生物（688062）披露发行境外上市外资股（H股）获得中国证监会备案，11月20日股价上涨0.02%
迈威生物新型抗IL-11单克隆抗体9Mw3811获得NMPA批准，启动病理性瘢痕第二阶段临床试验
美股速递 · 11-11
迈威生物新型抗IL-11单克隆抗体9Mw3811获得NMPA批准，启动病理性瘢痕第二阶段临床试验
迈威生物与平安好医生达成深度合作，探索医疗健康服务创新模式
迈威生物官微 · 11-11
迈威生物与平安好医生达成深度合作，探索医疗健康服务创新模式
迈威生物(688062.SH)：9MW3811注射液临床试验申请获得国家药品监督管理局批准
智通财经 · 11-10
迈威生物(688062.SH)：9MW3811注射液临床试验申请获得国家药品监督管理局批准
每周股票复盘：迈威生物（688062）股东户数增9.15%，营收同比增301.03%
证券之星 · 11-02
每周股票复盘：迈威生物（688062）股东户数增9.15%，营收同比增301.03%
迈威生物（688062）2025年三季报简析：营收上升亏损收窄，盈利能力上升
证券之星 · 11-01
迈威生物（688062）2025年三季报简析：营收上升亏损收窄，盈利能力上升
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是治疗用生物制品的研发、生产与销售。公司的主要产品是抗体药物、技术服务。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物","latestPrice":39.94,"timestamp":1766732401000,"preClose":40.2,"halted":0,"volume":3347727,"delay":0,"changeRate":-0.0065,"floatShares":204000000,"shares":400000000,"eps":-2.3711,"marketStatus":"已收盘","change":-0.26,"latestTime":"12-26 15:00:01","open":40,"high":40.38,"low":39.68,"amount":134000000,"amplitude":0.0174,"askPrice":39.95,"askSize":33,"bidPrice":39.94,"bidSize":39,"shortable":0,"etf":0,"ttmEps":-2.3711,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":40.2,"symbolType":"stock_kcb","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":44.22,"lowLimit":36.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":399600000,"isCdr":false,"pbRate":20.97,"roa":"--","roe":"--","epsLYR":-2.61,"committee":0.072727,"marketValue":15960000000,"turnoverRate":0.0164,"status":1,"afterMarket":{"amount":0,"volume":0,"close":39.94,"buyVolume":0,"sellVolume":0,"time":1766734437768,"indexStatus":"已收盘 12-26 15:30:00","preClose":40.2},"floatMarketCap":8155000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2594244551","title":"每周股票复盘：迈威生物（688062）9MW1911获FDA许可拟美开展IIa期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2594244551","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594244551?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:29","pubTimestamp":1766860149,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，迈威生物报收于39.94元，较上周的39.61元上涨0.83%。本周关注点公司公告汇总：9MW1911注射液临床试验申请获FDA许可，拟在美国开展针对中重度COPD患者的IIa期临床研究。该药品为自主开发的抗ST2单克隆抗体，已在境内完成IIa期临床试验，安全性良好，药代动力学和初步疗效数据支持进一步开发。目前IIb期临床试验正在积极入组，计划2026年底启动III期研究。表决程序合法，表决结果有效。董事会成员仍为9名，符合相关法规要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2594237416","title":"迈威生物（688062）披露取消监事会及修订公司章程议案获股东大会通过，12月25日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237416","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237416?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:33","pubTimestamp":1766673197,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，迈威生物报收于40.2元，较前一交易日上涨0.9%，最新总市值为160.64亿元。近日，迈威（上海）生物科技股份有限公司召开2025年第三次临时股东大会，审议通过了《关于取消监事会、修订〈公司章程〉及相关议事规则的议案》及《关于修订部分公司治理制度的议案》。其中，取消监事会及修订公司章程为特别决议议案，已获出席股东所持表决权2/3以上通过；其余治理制度修订为普通决议议案，获1/2以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","002755","000661","02096","01801","02142","688428","LU2097828557.USD","LU2097828631.EUR","LU2580892862.HKD","LU1969619763.USD","09995","03692","LU0502904849.HKD","BK1589","BK0057","LU1328615791.USD","LU1064131003.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","BK0028","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU2097828474.EUR","BK1161","603087","LU2148510915.USD","BK0188","02509","BK0060","688062","BK1593","688336","LU2495084118.USD","688331","01530","LU1997245094.SGD","LU2097828714.EUR","600276","LU1781817850.SGD","LU1146622755.USD","06978","BK1574","LU2097828805.USD","BK0012","BK0239","BK0196","01167"],"gpt_icon":0},{"id":"2593475668","title":"迈威生物（688062）披露股份回购实施结果公告，12月24日股价上涨0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475668?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:51","pubTimestamp":1766569908,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，迈威生物报收于39.84元，较前一交易日上涨0.99%，最新总市值为159.2亿元。该股当日开盘39.84元，最高40.7元，最低39.46元，成交额达2.14亿元，换手率为2.63%。公司近日发布公告称，迈威生物于2025年6月26日启动股份回购，回购期限为12个月，回购资金总额预计2,500万元至5,000万元，回购价格上限调整为66.46元/股。回购股份将用于员工持股计划或股权激励，目前存放于回购专用证券账户，不影响公司控制权及上市地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400029043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2593649030","title":"迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2593649030","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593649030?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:51","pubTimestamp":1766494262,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》(Study May Proceed Notification)，9MW1911注射液临床试验申请正式获得FDA许可。9MW1911为一款基于高效B淋巴细胞筛选平台自主研发的创新单克隆抗体，属于治疗用生物制品1类，可高亲和力结合ST2受体，从而阻断IL33/ST2 信号通路。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"迈威生物(688062.SH)：9MW1911注射液临床试验申请获得FDA许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2591615393","title":"12月15日迈威生物跌6.05%，新华优选分红混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615393","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615393?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:34","pubTimestamp":1765784042,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日迈威生物跌6.05%创60日新低，收盘报38.33元，换手率4.35%，成交量8.87万手，成交额3.47亿元。重仓迈威生物的前十大公募基金请见下表：该股最近90天内共有8家机构给出评级，买入评级6家，增持评级2家；过去90天内机构目标均价为56.03。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共26家，其中持有数量最多的公募基金为新华基金的新华优选分红混合A。该公募基金现任基金经理为赵强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"1152178837","title":"迈威生物宣布创新抗St2抗体9Mw1911的IIa期试验结果显示年严重 COPD 加重率降低超过 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152178837","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152178837?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:01","pubTimestamp":1764597675,"startTime":"0","endTime":"0","summary":"迈威生物宣布其创新抗St2抗体9Mw1911的IIa期试验结果，年严重COPD加重率降低超过40%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2588253057","title":"迈威生物（688062）自愿披露关于9MW1911临床研究进展的公告，12月1日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588253057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588253057?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:48","pubTimestamp":1764582534,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，迈威生物报收于42.91元，较前一交易日下跌0.44%，最新总市值为171.47亿元。近日，迈威生物发布自愿披露关于9MW1911临床研究进展的公告。研究结果显示，9MW1911各剂量组安全性与耐受性良好，不良事件发生率与安慰剂组相近，免疫原性均为阴性。在推荐剂量下，中重度COPD急性加重年化发生率较安慰剂组降低超30%，重度急性加重年化发生率降低超40%，且发生重度急性加重的患者比例显著降低。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2588371664","title":"百利天恒收到里程碑付款；迈威生物披露阻塞性肺病新药临床进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2588371664","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588371664?lang=zh_cn&edition=full","pubTime":"2025-12-01 07:13","pubTimestamp":1764544408,"startTime":"0","endTime":"0","summary":"｜2025年12月1日星期一｜NO.1百利天恒收到百时美施贵宝里程碑付款百利天恒公告，子公司SystImmune已收到由百时美施贵宝支付的2.5亿美元里程碑付款。据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512013578546745.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512013578546745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK0239","02615","688506","BK1515","688062","159938","BK1161","91194","BK1574"],"gpt_icon":0},{"id":"2587716796","title":"迈威生物：9MW1911临床研究进展顺利COPD急性加重年化发生率显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=2587716796","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587716796?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:11","pubTimestamp":1764490269,"startTime":"0","endTime":"0","summary":"迈威生物(688062.SH)公告称，公司自主研发的创新药9MW1911 已完成在中重度慢性阻塞性肺疾病（COPD）患者中的IIa 期临床研究，所有剂量组均表现出良好的安全性与耐受性。在IIb 期研究推荐剂量下，中重度COPD 急性加重年化发生率较安慰剂组降低超30%，重度急性加重年化发生率降低超40%，且发生重度急性加重的患者比例显著降低。目前，公司正在积极推进9MW1911 在COPD 适应症开展的IIb 期临床研究。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025113000002386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2586686982","title":"迈威生物（688062）披露关于开立、变更部分募集资金专用账户并重新签订三方及四方监管协议的公告，11月26日股价上涨2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586686982","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586686982?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:10","pubTimestamp":1764166204,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘，迈威生物报收于44.04元，较前一交易日上涨2.47%，最新总市值为175.98亿元。近日，迈威生物发布公告称，公司于2025年11月26日召开董事会及监事会会议，审议通过了关于开立、变更部分募集资金专用账户并重新签订三方及四方监管协议的议案。本次变更不改变募集资金用途，不影响募投项目正常运行。公司及全资子公司将与中信银行、保荐机构国泰海通证券签署新的监管协议。监事会及保荐机构均对本次事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600038761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2585539894","title":"新股消息 | 迈威生物(688062.SH)港股IPO获中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2585539894","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585539894?lang=zh_cn&edition=full","pubTime":"2025-11-24 13:52","pubTimestamp":1763963549,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月21日，中国证监会国际合作司发布《关于迈威(上海)生物科技股份有限公司境外发行上市备案通知书》。迈威生物拟发行不超过62,664,600股境外上市普通股并在香港联合交易所上市。据招股书，迈威生物是一家主要专注于自主开发肿瘤和年龄相关疾病药物并处于商业化阶段的制药公司。迈威生物2025年第三季度报告显示，前三季度实现营业收入5.65亿元，同比增长301.03%；归属于上市公司股东的净利润为亏损5.98亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2585753108","title":"每周股票复盘：迈威生物（688062）获H股发行备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2585753108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585753108?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:50","pubTimestamp":1763833821,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，迈威生物报收于40.1元，较上周的45.25元下跌11.38%。本周，迈威生物11月17日盘中最高价报45.19元。迈威生物当前最新总市值160.24亿元，在化学制药板块市值排名30/151，在两市A股市值排名1124/5167。本周关注点公司公告汇总：迈威生物获中国证监会关于H股发行上市的备案通知。完成发行后，公司须在15个工作日内向中国证监会报告发行情况。若备案期间发生重大事项，需通过中国证监会备案管理系统及时报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2585177229","title":"【财闻联播】美团将在全国建设“骑手公寓”！兆威机电、迈威生物港股IPO获证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2585177229","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585177229?lang=zh_cn&edition=full","pubTime":"2025-11-22 23:11","pubTimestamp":1763824277,"startTime":"0","endTime":"0","summary":"宏观动态《大型网络平台个人信息保护规定（征求意见稿）》公开征求意见国家互联网信息办公室、公安部就《大型网络平台个人信息保护规定（征求意见稿）》公开征求意见。征求意见稿提出，大型网络平台服务提供者应当将在中华人民共和国境内运营中收集和产生的个人信息存储在境内。确需向境外提供的，应当符合国家数据出境安全管理有关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511223572081458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0052750758.USD","LU0128522157.USD","LU0463099449.HKD","METmain","HMTD.SI","BK1142","LU0269904917.USD","LU1719994722.HKD","003021","LU0228659784.USD","BK0239","LU0359201885.HKD","LU0561508036.HKD","MPNGY","LU0499858602.USD","BK1591","LU0828238088.HKD","LU0231483743.USD","LU0326948709.USD","BK1604","LU0287142896.SGD","LU0873338254.USD","LU0164872284.USD","LU0054237671.USD","LU0348805143.USD","LU0449509016.USD","LU0588545730.USD","LU0047713382.USD","LU0051755006.USD","LU0164880469.USD","LU2476274308.USD","LU1481107354.HKD","LU0039217434.USD","LU0633140727.USD","IE0008368742.USD","LU0821914370.USD","LU0605514214.HKD","LU1831875114.USD","LU0049853897.USD","LU0345775950.USD","LU1868837565.USD","LU0577902454.USD","LU0149721374.USD","LU0672654166.SGD","LU0828237510.HKD","LU0650527681.SGD","LU0918141887.USD","688062","03690","LU0531971595.HKD"],"gpt_icon":1},{"id":"2584137213","title":"迈威生物（688062）披露发行境外上市外资股（H股）获得中国证监会备案，11月20日股价上涨0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584137213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584137213?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:12","pubTimestamp":1763647947,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘，迈威生物报收于41.76元，较前一交易日上涨0.02%，最新总市值为166.87亿元。公司近日发布公告称，迈威（上海）生物科技股份有限公司于近日收到中国证监会出具的《关于迈威（上海）生物科技股份有限公司境外发行上市备案通知书》。备案通知书要求公司在备案后如发生重大事项，需通过中国证监会备案管理系统报告，并在完成发行上市后15个工作日内报告发行情况。本次发行上市尚需取得香港相关监管机构批准，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"1113502187","title":"迈威生物新型抗IL-11单克隆抗体9Mw3811获得NMPA批准，启动病理性瘢痕第二阶段临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1113502187","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113502187?lang=zh_cn&edition=full","pubTime":"2025-11-11 22:02","pubTimestamp":1762869757,"startTime":"0","endTime":"0","summary":"迈威生物新型抗IL-11单克隆抗体9Mw3811获得NMPA批准，启动病理性瘢痕第二阶段临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"gpt_icon":0},{"id":"2582958384","title":"迈威生物与平安好医生达成深度合作，探索医疗健康服务创新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2582958384","media":"迈威生物官微","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582958384?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:09","pubTimestamp":1762819740,"startTime":"0","endTime":"0","summary":"迈威生物（688062.SH），一家全产业链布局的创新型生物制药公司，与平安健康医疗科技有限公司（以下简称：平安好医生）宣布达成深度业务合作。双方将共同打造多领域产品线上线下一体化解决 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251111/c672382290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688062","159760"],"gpt_icon":0},{"id":"2582182315","title":"迈威生物(688062.SH)：9MW3811注射液临床试验申请获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2582182315","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582182315?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:22","pubTimestamp":1762762974,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW3811注射液用于病理性瘢痕适应症的II期临床试验申请获得批准。9MW3811是公司自主研发的一款靶向人IL-11的人源化单克隆抗体，属于治疗用生物制品1类，拥有自主知识产权。9MW3811通过高亲和力结合IL-11，有效抑制IL-11/IL-11Rα信号通路的异常激活，从而干预纤维化相关疾病的病理进展。其核心优势包括：1)更高的靶点亲和力与信号阻断能力;2)超过一个月的长半衰期，更适用于需要长期给药的慢性疾病治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688062","BK0239"],"gpt_icon":0},{"id":"2580990478","title":"每周股票复盘：迈威生物（688062）股东户数增9.15%，营收同比增301.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580990478","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580990478?lang=zh_cn&edition=full","pubTime":"2025-11-02 01:32","pubTimestamp":1762018331,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，迈威生物报收于47.48元，较上周的42.74元上涨11.09%。本周，迈威生物10月31日盘中最高价报48.48元。迈威生物当前最新总市值189.73亿元，在化学制药板块市值排名28/151，在两市A股市值排名1005/5163。股本股东变化截至2025年9月30日，迈威生物股东户数为1.96万户，较6月30日增加1641.0户，增幅9.15%。业绩披露要点迈威生物2025年三季报显示，前三季度主营收入5.66亿元，同比上升301.03%；归母净利润-5.98亿元，同比上升13.89%；扣非净利润-6.22亿元，同比上升12.91%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0},{"id":"2580417876","title":"迈威生物（688062）2025年三季报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2580417876","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580417876?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:46","pubTimestamp":1761950798,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2025年三季报。截至本报告期末，公司营业总收入5.66亿元，同比上升301.03%，归母净利润-5.98亿元，同比上升13.89%。按单季度数据看，第三季度营业总收入4.65亿元，同比上升1717.41%，第三季度归母净利润-4634.11万元，同比上升81.4%。本报告期迈威生物盈利能力上升，毛利率同比增幅0.74%，净利率同比增幅78.52%。持有迈威生物最多的基金为新华优选分红混合A，目前规模为8.84亿元，最新净值0.9294，较上一交易日下跌1.78%，近一年上涨70.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766947517476,"stockEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":-0.0931},{"period":"3month","weight":-0.1717},{"period":"6month","weight":0.3955},{"period":"1year","weight":0.9019},{"period":"ytd","weight":0.9772}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19583人(较上一季度增加9.15%)","perCapita":"10425股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"39960万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是治疗用生物制品的研发、生产与销售。公司的主要产品是抗体药物、技术服务。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物,688062,迈威生物股票,迈威生物股票老虎,迈威生物股票老虎国际,迈威生物行情,迈威生物股票行情,迈威生物股价,迈威生物股市,迈威生物股票价格,迈威生物股票交易,迈威生物股票购买,迈威生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}